Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
biologically active human fecal material (OpenBiome)
- Development stage
- Unknown
- Lead developer
- OpenBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Biologically active human fecal material is a fecal microbiota transplant (FMT) product sourced, pre-screened, and processed by OpenBiome. It consists of a complete community of microorganisms, including bacteria, fungi, and viruses, derived from healthy donor stool. The therapy is designed to restore a healthy and diverse gut microbiome in patients suffering from dysbiosis. It has been investigated in clinical trials, such as a pilot study led by Najwa Elnachef (NCT02428361), for the treatment of acute or chronic pouchitis in patients who have undergone proctocolectomy with ileal pouch-anal anastomosis (IPAA). The product is typically administered as a 250 mL suspension via endoscopic routes such as pouchoscopy or colonoscopy.
- Other names
- fecal microbiota transplantFMTOpenBiome FMT
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)Microbial short-chain fatty acid production pathwaysAHR (Aryl hydrocarbon receptor)GPBAR1FFAR3 (Free fatty acid receptor 3)HDAC (HDAC family)FFAR2TLR (Toll-like receptors)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on biologically active human fecal material (OpenBiome).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on biologically active human fecal material (OpenBiome).